Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures.

Kevin RC, Kovach AL, Lefever TW, Gamage TF, Wiley JL, McGregor IS, Thomas BF.

Forensic Toxicol. 2019 Jan;37(1):17-26. doi: 10.1007/s11419-018-0430-0. Epub 2018 Jun 28.

PMID:
30705707
2.

Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors.

Gamage TF, Farquhar CE, McKinnie RJ, Kevin RC, McGregor IS, Trudell ML, Wiley JL, Thomas BF.

J Pharmacol Exp Ther. 2019 Mar;368(3):414-422. doi: 10.1124/jpet.118.254425. Epub 2018 Dec 14.

PMID:
30552295
3.

Synthesis and pharmacology of new psychoactive substance 5F-CUMYL-P7AICA, a scaffold- hopping analog of synthetic cannabinoid receptor agonists 5F-CUMYL-PICA and 5F-CUMYL-PINACA.

Banister SD, Adams A, Kevin RC, Macdonald C, Glass M, Boyd R, Connor M, McGregor IS, Havel CM, Bright SJ, Vilamala MV, Lladanosa CG, Barratt MJ, Gerona RR.

Drug Test Anal. 2018 Aug 27. doi: 10.1002/dta.2491. [Epub ahead of print]

PMID:
30151911
4.

Author Correction: Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community.

Suraev A, Lintzeris N, Stuart J, Kevin RC, Blackburn R, Richards E, Arnold JC, Ireland C, Todd L, Allsop DJ, McGregor IS.

Sci Rep. 2018 Aug 2;8(1):11850. doi: 10.1038/s41598-018-30164-8.

5.

Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community.

Suraev A, Lintzeris N, Stuart J, Kevin RC, Blackburn R, Richards E, Arnold JC, Ireland C, Todd L, Allsop DJ, McGregor IS.

Sci Rep. 2018 Jul 5;8(1):10154. doi: 10.1038/s41598-018-28127-0. Erratum in: Sci Rep. 2018 Aug 2;8(1):11850.

6.

Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA.

Gamage TF, Farquhar CE, Lefever TW, Marusich JA, Kevin RC, McGregor IS, Wiley JL, Thomas BF.

J Pharmacol Exp Ther. 2018 May;365(2):437-446. doi: 10.1124/jpet.117.246983. Epub 2018 Mar 16.

PMID:
29549157
7.

The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs.

Banister SD, Olson A, Winchester M, Stuart J, Edington AR, Kevin RC, Longworth M, Herrera M, Connor M, McGregor IS, Gerona RR, Kassiou M.

Drug Test Anal. 2018 Jan 19. doi: 10.1002/dta.2362. [Epub ahead of print]

PMID:
29350472
8.

Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MN-18.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Gamage TF, Fennell TR, Wiley JL, McGregor IS, Thomas BF.

Drug Test Anal. 2018 Jan;10(1):137-147. doi: 10.1002/dta.2262. Epub 2017 Sep 28.

9.

In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA.

Kevin RC, Lefever TW, Snyder RW, Patel PR, Fennell TR, Wiley JL, McGregor IS, Thomas BF.

Forensic Toxicol. 2017;35(2):333-347. doi: 10.1007/s11419-017-0361-1. Epub 2017 Mar 10.

10.

Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues.

Longworth M, Banister SD, Boyd R, Kevin RC, Connor M, McGregor IS, Kassiou M.

ACS Chem Neurosci. 2017 Oct 18;8(10):2159-2167. doi: 10.1021/acschemneuro.7b00267. Epub 2017 Aug 11.

PMID:
28792725
11.

Vaping Synthetic Cannabinoids: A Novel Preclinical Model of E-Cigarette Use in Mice.

Lefever TW, Marusich JA, Thomas BF, Barrus DG, Peiper NC, Kevin RC, Wiley JL.

Subst Abuse. 2017 Apr 7;11:1178221817701739. doi: 10.1177/1178221817701739. eCollection 2017.

12.

Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA.

Kevin RC, Wood KE, Stuart J, Mitchell AJ, Moir M, Banister SD, Kassiou M, McGregor IS.

J Psychopharmacol. 2017 Jun;31(6):757-769. doi: 10.1177/0269881116684336. Epub 2017 Jan 16.

PMID:
28093016
13.

Thermolytic Degradation of Synthetic Cannabinoids: Chemical Exposures and Pharmacological Consequences.

Thomas BF, Lefever TW, Cortes RA, Grabenauer M, Kovach AL, Cox AO, Patel PR, Pollard GT, Marusich JA, Kevin RC, Gamage TF, Wiley JL.

J Pharmacol Exp Ther. 2017 Apr;361(1):162-171. doi: 10.1124/jpet.116.238717. Epub 2017 Jan 13. Erratum in: J Pharmacol Exp Ther. 2017 May;361(2):245.

14.

Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.

Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Glass M, Connor M, McGregor IS, Kassiou M.

ACS Chem Neurosci. 2015 Sep 16;6(9):1546-59. doi: 10.1021/acschemneuro.5b00112. Epub 2015 Jul 17.

PMID:
26134475
15.

Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135.

Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, Beinat C, Buchanan AS, Hibbs DE, Glass M, Connor M, McGregor IS, Kassiou M.

ACS Chem Neurosci. 2015 Aug 19;6(8):1445-58. doi: 10.1021/acschemneuro.5b00107. Epub 2015 May 8.

PMID:
25921407
16.

Defensive aggregation (huddling) in Rattus norvegicus toward predator odor: individual differences, social buffering effects and neural correlates.

Bowen MT, Kevin RC, May M, Staples LG, Hunt GE, McGregor IS.

PLoS One. 2013 Jul 29;8(7):e68483. doi: 10.1371/journal.pone.0068483. Print 2013.

Supplemental Content

Loading ...
Support Center